Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06312540
Other study ID # PERSONA
Secondary ID 15397/2018
Status Recruiting
Phase
First received
Last updated
Start date September 2, 2020
Est. completion date September 1, 2024

Study information

Verified date March 2024
Source Azienda Ospedaliero, Universitaria Pisana
Contact Carmelo Chisari, Medical
Phone 001 050996907
Email carmelo.chisari@unipi.it
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The aim is to carry out a first clinical study, to expand existing knowledge about the neurophysiological mechanisms underlying post-stroke recovery. The information acquired during this phase will be used as building blocks to develop customized protocols. Understanding the mechanisms underlying stroke-induced motor deficits and motor recovery is mandatory to improve clinicians; ability to guide the repair of the affected neural structures. The motor system comprises a network of cortical and subcortical areas interacting via excitatory and inhibitory circuits, thereby governing motor behaviour. Stroke lesions cause neural dysfunction both at the lesion site and in remote brain regions. Abnormal interactions among cortical regions within the motor network contribute to the motor impairment after stroke. Longitudinal analysis of neural activity and connectivity can help to understand the pathophysiology mechanisms underlying functional impairment and recovery after stroke. Analysis of the data will try to extract biomarkers of plasticity and recovery that will be used to design customized therapeutic interventions.


Description:

Consecutive stroke patients admitted to the Stroke Unit will be enrolled. Both ischaemic and hemorrhagic strokes above 18-years of age will be recruited. A dedicated encrypted database will be developed, and the following items will be collected: age, sex, aetiology of stroke, TOAST classification, Modified Rankin Scale before stroke and at the discharge from the Stroke Unit and after 3 months from the stroke (in survivors), NIHSS at the onset, at the discharge from the Stroke Unit, and after 3 months from the stroke (in survivors), neuroimaging studies at the onset (CT, AngioCT, MRI) and the follow up, acute treatment (for ischaemic strokes, fibrinolysis, primary or rescue thrombectomy, standard care), comorbidity (diabetes, hypertension, smoking habits, heart disease, atrial fibrillation, etc), biochemical and genetic biomarkers from blood and urine. The clinical and biochemical section of our database will include "yes or no" dichotomic items agreed by all groups in a preliminary consensus phase, specifically designed to define the clinical features known to be relevant in strokes.


Recruitment information / eligibility

Status Recruiting
Enrollment 50
Est. completion date September 1, 2024
Est. primary completion date April 1, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - unilateral motor deficit (with or without other stroke- related symptoms or signs) - radiological evidence of unilateral, supratentorial cerebral ischemic lesion (or lesions) in the same arterial territory - stroke occurred in the last 4 days - absent or slight disability before stroke estimated by a modified Rankin Scale 0-2 Exclusion Criteria: - history of severe cognitive impairment - psychiatric comorbidities - end-stage organic diseases like cardiopulmonary, hepatic, renal failure, neoplasms, and whatever condition that could strongly reduce life expectation

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Italy AOUPisana Pisa Pi

Sponsors (3)

Lead Sponsor Collaborator
Azienda Ospedaliero, Universitaria Pisana Fondazione Don Carlo Gnocchi Onlus, Scuola Superiore Sant'Anna di Pisa

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary Brain activity Electroencephalography (EEG) power spectrum analysis 36 months
Primary Functional evaluation Fugl-Meyer Upper Limb (0-66) 36 months
Secondary Clinical scale Motricity Index (0-100)
Wolf Motor Function Test
36 months
Secondary Spasticity assessment Modified Ashworth Scale (0-4) 36 months
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06315192 - Stroke Alarm Efficacy Trial N/A
Completed NCT02111564 - A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients Phase 3
Active, not recruiting NCT05906420 - Posterior Circulation ASTRAL Prognostic Score
Completed NCT02430324 - The Multicenter Italian INCEPT (INfarto CErebrale Post-Traumatico) Study N/A
Not yet recruiting NCT06320431 - ACT-GLOBAL THROMBOLYSIS (ACT-WHEN-001) Domain Within the ACT-GLOBAL Adaptive Platform Trial-NCT06352632 Phase 3